---
layout: default
title: Pantoprazole
parent: High Evidence (L1-L2)
nav_order: 636
evidence_level: L1
indication_count: 6
---

# Pantoprazole
{: .fs-9 }

Evidence Level: **L1** | Predicted Indications: **6** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Pantoprazole: From Erosive Esophagitis to Active Peptic Ulcer Disease

## One-Sentence Summary

Pantoprazole is a proton pump inhibitor (PPI); per available literature its original FDA-labeled indication is the short-term treatment of erosive esophagitis (PMID 11402494), and no India registration record exists in this dataset.
The TxGNN model predicts it may also be effective for **active peptic ulcer disease**,
with **3 clinical trials** and **19 publications** currently supporting this direction.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | No India license text available (drug not marketed locally); per literature (PMID 11402494), originally FDA-labeled for short-term treatment of erosive esophagitis |
| Predicted New Indication | Active Peptic Ulcer Disease |
| TxGNN Prediction Score | 99.69% |
| Evidence Level | L1 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |

---

## Why is This Prediction Reasonable?

DrugBank's structured mechanism-of-action field for this record is currently a data gap. Based on the literature captured in this evidence pack, however, pantoprazole is a substituted benzimidazole that **irreversibly and selectively inhibits the gastric parietal cell H⁺/K⁺-ATPase (proton pump)**, blocking the final common step of acid secretion (PMID 19938880, 9017763). It has a relatively long duration of action compared with other PPIs and, per the same review, no clinically significant drug-drug interactions had been identified across numerous interaction studies at the time of that publication.

The original indication (erosive esophagitis/GERD, per PMID 11402494) and the predicted indication (active peptic ulcer disease) are both acid-related upper-GI disorders that share the same underlying pathophysiology: excess or unbuffered gastric acid damaging the mucosa. Since pantoprazole's mechanism acts directly on acid production regardless of the specific mucosal site (esophagus, stomach, or duodenum), extending its use from reflux esophagitis to peptic ulcer healing is mechanistically direct rather than speculative.

This is further reinforced by the repurposing rationale attached to the top-ranked prediction: pantoprazole's acid-suppressing mechanism both promotes ulcer healing and supports Helicobacter pylori eradication regimens, a use already extensively documented in the clinical trial and literature evidence below.

---

## Clinical Trial Evidence

| Trial Number | Phase | Status | Enrollment | Key Findings |
|---------|------|------|------|---------|
| [NCT02084420](https://clinicaltrials.gov/study/NCT02084420) | Phase 3 | Completed | 323 | Multicenter, double-blind, active-controlled comparison of ilaprazole vs. pantoprazole triple therapy (7 days) for H. pylori eradication in H. pylori-positive gastric/duodenal ulcer patients |
| [NCT02197039](https://clinicaltrials.gov/study/NCT02197039) | N/A | Completed | 316 | Prospective study identifying risk factors for poor stigmata fading or early rebleeding after endoscopic hemostasis plus high-dose PPI infusion, to define criteria for second-look endoscopy |
| [NCT00930670](https://clinicaltrials.gov/study/NCT00930670) | Phase 4 | Completed | 320 | Evaluated whether PPIs (including pantoprazole) and statins interfere with clopidogrel's antiplatelet effect in patients on dual antiplatelet therapy after PCI |

---

## Literature Evidence

| PMID | Year | Type | Journal | Key Findings |
|------|-----|------|------|---------|
| [18824852](https://pubmed.ncbi.nlm.nih.gov/18824852/) | 2008 | RCT | Digestion | Compared intermittent vs. continuous IV pantoprazole infusion for preventing rebleeding in peptic ulcer bleeding |
| [15244210](https://pubmed.ncbi.nlm.nih.gov/15244210/) | 2003 | RCT | Hepato-gastroenterology | Compared lansoprazole vs. pantoprazole efficacy in active duodenal ulcer treatment and H. pylori eradication |
| [10632647](https://pubmed.ncbi.nlm.nih.gov/10632647/) | 2000 | RCT | Alimentary Pharmacology & Therapeutics | Evaluated pantoprazole + amoxicillin + azithromycin/clarithromycin regimens for H. pylori eradication in duodenal ulcer |
| [12752349](https://pubmed.ncbi.nlm.nih.gov/12752349/) | 2003 | RCT | Alimentary Pharmacology & Therapeutics | Compared three pantoprazole-based triple therapy regimens for H. pylori eradication and gastric ulcer healing |
| [16677158](https://pubmed.ncbi.nlm.nih.gov/16677158/) | 2006 | RCT | Journal of Gastroenterology and Hepatology | Pantoprazole infusion as adjuvant to endoscopic therapy reduced rebleeding in peptic ulcer bleeding |
| [38345252](https://pubmed.ncbi.nlm.nih.gov/38345252/) | 2024 | Systematic Review | American Journal of Gastroenterology | Network meta-analysis comparing P-CAB vs. PPI (including pantoprazole) efficacy/safety in healing Grade C/D esophagitis |
| [19938880](https://pubmed.ncbi.nlm.nih.gov/19938880/) | 2009 | Review | Clinical Drug Investigation | Reviews pantoprazole's irreversible H+/K+-ATPase inhibition, long duration of action, and lack of identified drug interactions |
| [10983736](https://pubmed.ncbi.nlm.nih.gov/10983736/) | 2000 | Review | Drugs | Comparative review noting esomeprazole gives better intragastric pH control than omeprazole, lansoprazole, and pantoprazole in GERD |
| [9017763](https://pubmed.ncbi.nlm.nih.gov/9017763/) | 1997 | Review | Pharmacotherapy | Reviews PPI mechanism (H+/K+-ATPase inhibition) and superiority over H2RAs in controlling gastric acid secretion |
| [38652367](https://pubmed.ncbi.nlm.nih.gov/38652367/) | 2024 | Preclinical/Animal | Inflammopharmacology | Rat model study of combined pantoprazole + mesenchymal stem cells on gastric ulcer healing via oxidative stress/inflammation/apoptosis pathways |

---

## India Market Information

Pantoprazole is currently **not marketed** in India per this dataset — no registration/license records are available (`total_licenses: 0`).

---

## Safety Considerations

**Drug Interactions**: A DDI database query returned **597 total interactions**. Notable Major-severity interactions include:

| Interacting Drug | Severity | Source |
|---|---|---|
| Acalabrutinib | Major | ddinter |
| Atazanavir | Major | ddinter |

Both involve drugs whose absorption is pH-dependent, consistent with pantoprazole's acid-suppressing mechanism reducing their bioavailability. Numerous additional Moderate-level interactions (e.g., hydrochlorothiazide, atorvastatin, apalutamide, bosutinib, amikacin) and Minor-level interactions (e.g., acetylsalicylic acid, axitinib, bortezomib) are also on record; full details require the complete DDI dataset.

Structured key warnings and contraindications (e.g., TFDA/local label text) are not yet available for this record.

---

## Conclusion and Next Steps

**Decision: Proceed with Guardrails**

**Rationale:**
Multiple completed Phase 3/Phase 4 trials and several RCTs directly support pantoprazole's efficacy in H. pylori eradication and peptic ulcer healing/rebleeding prevention (Evidence Level L1), giving a mechanistically direct and well-evidenced case for the predicted indication. However, local regulatory and safety data are missing, and the drug is not currently marketed in India.

**To proceed, the following is needed:**
- TFDA/CDSCO label warnings and contraindications (currently a blocking data gap, DG001)
- Formal DrugBank-sourced mechanism-of-action record (DG002)
- India market entry/registration pathway assessment, since the drug is currently unmarketed
- Route-of-administration compatibility confirmation (currently marked pending in the evidence pack)
- Trials or literature specifically targeting "active peptic ulcer disease" as a formal labeled outcome, since most current evidence addresses related but distinct endpoints (H. pylori eradication, bleeding-ulcer rebleeding prevention)
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

